Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

AVIR

Insider Sentiment (TTM):

Last Purchase:2026-05-18Last Sale:2024-12-10Shares Purchased (TTM):6,100Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:57,429,599Shares Outstanding:79,198,204Institutional Ownership Pct.:72.51%

Earnings Market Reaction:

Filing Date:2026-05-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Pharmaceutical Preparations

LLY JNJ ABBV MRK ABT PFE

Atea Pharmaceuticals, Inc. (AVIR) — SEC Financial Statements & Analysis

Atea Pharmaceuticals, Inc. (AVIR) files its annual 10-K and quarterly 10-Q reports directly with the SEC. The financial data below is sourced as-filed from EDGAR — balance sheet, income statement, and cash flow as reported, without normalization or third-party adjustments.

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	79	96	77	88	119	65	98	243	161	144	138	214
Available For Sale Securities Debt Securities Curr…	177	206	252	292	306	390	384	259	381	434	457	394
Prepaid Expense And Other Assets Current	7	9	7	6	8	8	4	4	7	12	8	13
Assets Current	263	311	336	386	434	462	487	506	549	590	603	621
Property Plant And Equipment Net	0	0	1	1	1	1	1	1	1	1	1	1
Restricted Cash Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Other Assets Noncurrent	3	3	5	4	4	0	2	1	1	1	1	1
Operating Lease Right Of Use Asset	0	1	1	1	1	1	1	2	2	2	2	2
Assets	267	315	343	392	440	465	491	510	553	595	608	626
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	9	13	4	9	7	4	6	5	21	4	0	4
Accrued Liabilities And Other Liabilities	23	26	16	10	14	13	19	20	19	27	18	11
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	33	40	20	20	22	19	25	27	41	32	19	16
Operating Lease Liability Noncurrent	-	0	0	0	1	1	1	1	1	2	2	2
Accrued Income Taxes Noncurrent	-	0	7	7	6	6	6	6	6	6	6	5
Liabilities	-	40	27	27	29	26	32	34	49	40	26	24
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	802	798	793	800	809	803	788	776	763	751	739	726
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0	1	-0	-0	0	-0	-0
Retained Earnings Accumulated Deficit	-568	-523	-478	-436	-398	-364	-331	-300	-259	-196	-157	-124
Stockholders Equity	234	275	316	364	411	439	459	476	504	555	582	602
Liabilities And Stockholders Equity	267	315	343	392	440	465	491	510	553	595	608	626
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	80	78	78	81	86	84	84	84	84	83	83	83
Shares Outstanding	80	78	78	81	86	84	84	84	84	83	83	83

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-22.73%	-9.45%	-	-	-	-	-	-	-	-	-	-
2025	7.43%	26.35%	17.23%	-2.89%	-15.32%	-7.23%	-9.43%	-0.57%	21.14%	-3.40%	3.21%	-16.60%
2024	-6.57%	-17.93%	-12.88%	17.74%	5.20%	2.45%	-0.58%	-3.20%	-8.14%	-2.33%	-3.67%	-3.33%
2023	-	-	-	-1.76%	-12.02%	-9.68%	-5.17%	-7.29%	16.72%	-7.09%	-14.87%	-16.48%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	7.89	7.82	16.66	19.17	19.94	24.85	19.33	19.02	13.28	18.24	31.93	38.42
Quick Ratio	7.67	7.59	16.32	18.87	19.56	24.44	19.17	18.87	13.11	17.86	31.50	37.63
Working Capital	229.83M	271.21M	315.96M	365.49M	411.96M	443.75M	461.72M	479.75M	507.45M	558.08M	584.42M	604.67M
Leverage & Debt
Debt to Equity	0.14	0.14	0.09	0.07	0.07	0.06	0.07	0.07	0.10	0.07	0.05	0.04
Debt Ratio	0.12	0.13	0.08	0.07	0.07	0.06	0.07	0.07	0.09	0.07	0.04	0.04
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-2.14	-1.94	-1.86	-1.63	-1.64	-2.00	-2.06	-2.09	-1.95	-1.63	-1.57	-1.27
Free Cash Flow Per Share TTM	-1.87	-1.62	-1.70	-1.40	-1.48	-1.61	-1.50	-1.44	-1.14	-1.02	-1.02	-1.06
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Revenue Growth (1Y)	-	-	-	-	-	-	-	-	-	-	-100.00%	-100.00%
Net Income Growth (1Y)	21.53%	-5.96%	-15.51%	-22.65%	-14.77%	23.85%	32.60%	65.80%	49.73%	17.30%	-468.05%	-783.67%
EPS Growth (1Y)	30.68%	-2.76%	-9.77%	-22.19%	-16.01%	22.57%	31.00%	64.12%	48.69%	17.09%	-467.42%	-782.51%
Valuation Metrics
P/E TTM	-2.51	-1.84	-1.56	-2.21	-1.83	-1.68	-1.63	-1.58	-2.07	-1.87	-1.91	-2.94
P/B	1.82	1.06	0.73	0.83	0.62	0.64	0.62	0.59	0.67	0.46	0.43	0.52
Market Cap	426.09M	290.94M	229.25M	301.49M	254.63M	282.29M	282.81M	278.88M	339.02M	254.34M	250.20M	311.91M
Enterprise Value	346.77M	195.23M	151.91M	213.77M	135.23M	217.59M	184.35M	35.49M	178.11M	110.52M	112.31M	98.21M
Calculated Values
Free Cash Flow TTM	-147.86M	-132.03M	-134.21M	-116.87M	-126.20M	-135.50M	-126.94M	-121.49M	-95.41M	-85.40M	-85.11M	-88.78M
Net Debt	-79.32M	-95.71M	-77.34M	-87.72M	-119.39M	-64.70M	-98.46M	-243.39M	-160.91M	-143.82M	-137.89M	-213.70M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-05-18Purchase

Owner: Murphy, Polly A.

Title: -

Shares: 6,100

Price/Share: $4.17

Value: $25,437.00

Shares Owned: 92,145

Relationship: Director

Ownership: Direct

2025-05-18Purchase

Owner: Murphy, Polly A.

Title: -

Shares: 6,100

Price/Share: $4.17

Value: $25,437.00

Shares Owned: 92,145

Relationship: Director

Ownership: Direct

2025-01-16Purchase

Owner: Berger, Franklin M

Title: -

Shares: 10,000

Price/Share: $3.36

Value: $33,600.00

Shares Owned: 476,897

Relationship: Director

Ownership: Direct

2024-12-10Sale

Owner: Berger, Franklin M

Title: -

Shares: 359,606

Price/Share: $2.85

Value: $1,024,877.10

Shares Owned: 451,897

Relationship: Director

Ownership: Direct

2024-09-19Sale

Owner: Sommadossi, Jean-Pierre

Title: President, CEO, and Chairman

Shares: 1,841

Price/Share: $4.00

Value: $7,364.00

Shares Owned: 5,866,025

Relationship: Director,Officer

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-05-18	Murphy, Polly A.	Director	-	Direct	Purchase	6,100	4.17	$25,437.00	92,145	4/A
2025-05-18	Murphy, Polly A.	Director	-	Direct	Purchase	6,100	4.17	$25,437.00	92,145	4
2025-01-16	Berger, Franklin M	Director	-	Direct	Purchase	10,000	3.36	$33,600.00	476,897	4/A
2024-12-10	Berger, Franklin M	Director	-	Direct	Sale	359,606	2.85	$1,024,877.10	451,897	4
2024-09-19	Sommadossi, Jean-Pierre	Director,Officer	President, CEO, and Chairman	Indirect	Sale	1,841	4.00	$7,364.00	5,866,025	4
2024-06-20	Polsky, Bruce	Director	-	Direct	Sale	17,544	3.49	$61,228.56	65,606	4
2024-06-05	Sommadossi, Jean-Pierre	Director,Officer	President, CEO, and Chairman	Indirect	Sale	1,006	4.00	$4,024.00	5,923,994	4
2024-02-01	Hammond, Janet Mj	Officer	Chief Development Officer	Direct	Sale	14,029	3.84	$53,871.36	35,362	4
2024-02-01	Vavricka, John	Officer	Chief Commercial Officer	Direct	Sale	11,819	3.84	$45,384.96	21,515	4
2024-02-01	Horga, Maria Arantxa	Officer	Chief Medical Officer	Direct	Sale	15,870	3.84	$60,940.80	25,664	4
2024-02-01	Sommadossi, Jean-Pierre	Director,Officer	President, CEO, and Chairman	Direct	Sale	56,910	3.85	$219,103.50	116,557	4
2024-02-01	Foster, Wayne	Officer	EVP, Chief Accounting Officer	Direct	Sale	12,477	3.84	$47,911.68	20,857	4
2024-02-01	Corcoran, Andrea	Officer	See Remarks	Direct	Sale	15,843	3.84	$60,837.12	670,208	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

72.51%

Inst. Shares: 57,429,599

Shares Outstanding: 79,198,204

2025-12-31

67.85%

Inst. Shares: 55,294,407

Shares Outstanding: 81,495,352

2025-09-30

65.72%

Inst. Shares: 51,952,566

Shares Outstanding: 79,052,154

2025-06-30

61.28%

Inst. Shares: 51,317,174

Shares Outstanding: 83,747,335

2025-03-31

60.70%

Inst. Shares: 51,687,849

Shares Outstanding: 85,159,254

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	57,429,599	79,198,204	72.51%
2025-12-31	55,294,407	81,495,352	67.85%
2025-09-30	51,952,566	79,052,154	65.72%
2025-06-30	51,317,174	83,747,335	61.28%
2025-03-31	51,687,849	85,159,254	60.70%
2024-12-31	54,921,503	84,264,715	65.18%
2024-09-30	56,587,292	84,422,000	67.03%
2024-06-30	55,415,935	84,253,700	65.77%
2024-03-31	51,685,923	83,916,193	61.59%
2023-12-31	51,975,850	83,389,750	62.33%
2023-09-30	53,757,454	83,399,769	64.46%
2023-06-30	53,583,461	83,399,377	64.25%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Atea Pharmaceuticals, Inc. (AVIR) — SEC Financial Statements & Analysis

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.